Diabetic Boot Company20 Oct 2016 22:25
Have been looking at what the Diabetic Boot Company have been doing since it was announced that LIFE intends to arrange an RTO with them. From their website for they say the following:-
Autumn is traditionally 'busy season' for congresses and exhibitions. As healthcare professionals and business folk return to their desks and clinics after the summer, calendars are often full of symposia and conferences at which to share ideas, information and the latest research.
PulseFlow Technologies is no different and our calendar for the autumn is looking pretty hectic! Next week we'll be attending the Nordic Diabetic Foot congress in Copenhagen, Denmark, and exhibiting at the Symposium on Advanced Wound Care (SAWC) Fall meeting in Las Vegas, USA - a multidisciplinary forum for all members of the wound care team and the first outing for our new booth!
Our European team will then turn their focus to the Pisa International Diabetic Foot Course, which combines lectures and in-clinic training, while our US team set up for Desert Foot in Phoenix, Arizona, focussing on both diabetes-related and non-diabetes-related lower limb pathologies.
Then, in November, it's on to Medica in Dusseldorf, Germany - the world's leading trade fair for the medical industry - and Diabetes Professional Care in London, UK.
The Pisa International DF Course was held between 12 and 15 October and the company are currently at the Desert Foot Conference which is on between 19 and 22 October. So the publicity goes on and DBC were a sponsor of the Pisa event.
Back in February 2016, Les Lindsay the CEO of DBC advised Master Investor that they gained the green light, FDA 510k clearance, in December 2015, which was a huge milestone for them. The next biggest challenge was to get final sign-off on a US reimbursement rate at a high enough level. He guessed that they were now 85% through that process, so a very significant short-term milestone was to have that rate approved by CMS/Medicare before May 2016. That meant that they had clearance to market and a reimbursement rate to go forth and multiply in the DFU plague present in the USA. After the USA, with existing regulatory affairs clearances (CE mark etc.) he looked for significant revenues coming from Distribution partners already signed up. All of the above was dependent upon ramping up production capacity in the short term, and they were probably 90% complete on that, awaiting formal contracts being signed up. They were to commission large scale cost effectiveness / health economics studies in 2016, and anticipated reporting by 2017. My thought is that that might link in with the RTO perhaps being before the year end. It looks quite an exciting prospect and I am hopeful that shareholders, of which I and my wife are, will see a material increase in our investment.